Merck announces positive results from phase 2 trial evaluating coformulation of vibostolimab, pembrolizumab in lung cancer patients Ruchika Sharma10 Dec 2023 2:00 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced full results from the non-registrational Phase 2 KeyVibe-002...
Merck to stop phase 3 trial of Keytruda plus Lynparza for lung cancer patients Ruchika Sharma8 Dec 2023 3:19 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating...
MSD wins DCGI nod for Keytruda for treatment of triple negative breast cancer, renal cell carcinoma Ruchika Sharma26 Oct 2023 11:32 AM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
European Commission nod to Merck Keytruda for non-small cell lung cancer at high risk of recurrence Ruchika Sharma17 Oct 2023 3:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Commission (EC) has approved KEYTRUDA,...
Merck gets USFDA nod for neoadjuvant/ adjuvant Keytruda for resectable non-small cell lung cancer Ruchika Sharma17 Oct 2023 12:54 PM ISTThe approval marks the sixth NSCLC indication for KEYTRUDA.
Merck gets positive EU CHMP opinion for Keytruda as adjuvant treatment for adults with Non-Small Cell Lung Cancer Ruchika Sharma18 Sept 2023 11:30 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency’s Committee for Medicinal...
Gilead Sciences Trodelvy, Keytruda combo study demonstrates promising clinical activity in first-line Metastatic Non-Small Cell Lung Cancer Ruchika Sharma12 Sept 2023 2:30 PM ISTFoster City: Gilead Sciences, Inc. has announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy...
Merck, Portage Biotech collaborate to evaluate Portage's next-generation adenosine antagonists in combination with Keytruda in solid tumors Ruchika Sharma10 Sept 2023 11:30 AM ISTWestport: Portage Biotech Inc., a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in...
Rare case of Lichen Planus in patient on Pembrolizumab reported Medha Baranwal2 July 2023 8:00 PM ISTPunjab: A recent case study published in Indian Dermatology Online Journal described developing a rare immune-related adverse side effect in a patient...
USFDA accepts application for Merck KEYTRUDA plus chemotherapy as treatment for Biliary Tract Cancer Ruchika Sharma9 Jun 2023 5:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for review...
MSD Pharma Gets CDSCO Panel Nod for additional indication of anticancer drug Pembrolizumab Dr. Divya Colin23 May 2023 6:00 PM ISTNew Delhi: Based on the global clinical trial data presented by drug major, MSD Pharmaceuticals, the Subject Expert Committee (SEC) functional under...
Desmoplastic melanoma patients respond "exceptionally" well to treatment with immunotherapy alone Dr. Kamal Kant Kohli5 May 2023 8:00 PM ISTUSA: A recent study has suggested that many patients with desmoplastic melanoma could avoid the risk of toxicity from combination therapies and...
